Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

AMPA receptor potentiators: application for depression and Parkinson's disease.

O'Neill MJ, Witkin JM.

Curr Drug Targets. 2007 May;8(5):603-20. Review.

PMID:
17504104
2.

AMPA receptor potentiators for the treatment of CNS disorders.

O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES.

Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94. Review.

PMID:
15180479
3.

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ.

J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. Epub 2003 May 2.

4.

LY404187: a novel positive allosteric modulator of AMPA receptors.

Quirk JC, Nisenbaum ES.

CNS Drug Rev. 2002 Fall;8(3):255-82. Review.

5.
6.

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

O'Neill MJ, Murray TK, Whalley K, Ward MA, Hicks CA, Woodhouse S, Osborne DJ, Skolnick P.

Eur J Pharmacol. 2004 Feb 20;486(2):163-74.

PMID:
14975705
7.

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA.

Behav Brain Res. 2010 Sep 1;212(1):41-8. doi: 10.1016/j.bbr.2010.03.039. Epub 2010 Mar 27.

PMID:
20347881
8.
9.

Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.

Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D.

Neuropharmacology. 2001 Jun;40(8):976-83.

PMID:
11406188
10.

LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES.

CNS Drug Rev. 2005 Spring;11(1):77-96. Review.

11.

Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo.

Vandergriff J, Huff K, Bond A, Lodge D.

Neuropharmacology. 2001 Jun;40(8):1003-9.

PMID:
11406191
12.

AMPA receptor potentiators as cognitive enhancers.

O'Neill MJ, Dix S.

IDrugs. 2007 Mar;10(3):185-92. Review.

PMID:
17351873
13.

Recent advances in positive allosteric modulators of the AMPA receptor.

Morrow JA, Maclean JK, Jamieson C.

Curr Opin Drug Discov Devel. 2006 Sep;9(5):571-9. Review.

PMID:
17002217
14.
15.

LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons.

Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES.

Neuropharmacology. 2001 Jun;40(8):992-1002.

PMID:
11406190
16.

AMPA receptors in the therapeutic management of depression.

Bleakman D, Alt A, Witkin JM.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):117-26. Review.

PMID:
17430149
17.

Enhancement of antidepressant potency by a potentiator of AMPA receptors.

Li X, Witkin JM, Need AB, Skolnick P.

Cell Mol Neurobiol. 2003 Jun;23(3):419-30.

PMID:
12825836
18.

Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy.

Harms JE, Benveniste M, Maclean JK, Partin KM, Jamieson C.

Neuropharmacology. 2013 Jan;64:45-52. doi: 10.1016/j.neuropharm.2012.06.008. Epub 2012 Jun 23.

20.

A role for AMPA receptors in mood disorders.

Alt A, Nisenbaum ES, Bleakman D, Witkin JM.

Biochem Pharmacol. 2006 Apr 28;71(9):1273-88. Epub 2006 Jan 24. Review.

PMID:
16442080
Items per page

Supplemental Content

Write to the Help Desk